Dearden S - Search Results

1

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.

Jenkins S, Yang JC, Jänne PA, Thress KS, Yu K, Hodge R, Weston S, Dearden S, Patel S, Cantarini M, Shepherd FA. Jenkins S, et al. Among authors: dearden s. J Thorac Oncol. 2017 Aug;12(8):1247-1256. doi: 10.1016/j.jtho.2017.05.002. Epub 2017 May 17. J Thorac Oncol. 2017. PMID: 28527899 Free article. Clinical Trial.

2

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

Board RE, Ellison G, Orr MC, Kemsley KR, McWalter G, Blockley LY, Dearden SP, Morris C, Ranson M, Cantarini MV, Dive C, Hughes A. Board RE, et al. Among authors: dearden sp. Br J Cancer. 2009 Nov 17;101(10):1724-30. doi: 10.1038/sj.bjc.6605371. Epub 2009 Oct 27. Br J Cancer. 2009. PMID: 19861964 Free PMC article. Clinical Trial.

3

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.

Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. Ellison G, et al. Among authors: dearden s. J Clin Pathol. 2013 Feb;66(2):79-89. doi: 10.1136/jclinpath-2012-201194. Epub 2012 Nov 21. J Clin Pathol. 2013. PMID: 23172555 Free PMC article. Review.

4

Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.

Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T, McCormack R. Douillard JY, et al. Among authors: dearden s. J Thorac Oncol. 2014 Sep;9(9):1345-53. doi: 10.1097/JTO.0000000000000263. J Thorac Oncol. 2014. PMID: 25122430 Free PMC article. Clinical Trial.

5

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, Hammett T, Cantarini M, Barrett JC. Thress KS, et al. Among authors: dearden s. Lung Cancer. 2015 Dec;90(3):509-15. doi: 10.1016/j.lungcan.2015.10.004. Epub 2015 Oct 9. Lung Cancer. 2015. PMID: 26494259 Free article.

6

EGFR T790M mutation testing within the osimertinib AURA Phase I study.

Dearden S, Brown H, Jenkins S, Thress KS, Cantarini M, Cole R, Ranson M, Jänne PA. Dearden S, et al. Lung Cancer. 2017 Jul;109:9-13. doi: 10.1016/j.lungcan.2017.04.011. Epub 2017 Apr 19. Lung Cancer. 2017. PMID: 28577957 Clinical Trial.

7

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden S, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam SS. Gray JE, et al. Among authors: dearden s. Clin Cancer Res. 2019 Nov 15;25(22):6644-6652. doi: 10.1158/1078-0432.CCR-19-1126. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439584 Free PMC article.

8

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

Dearden S, Stevens J, Wu YL, Blowers D. Dearden S, et al. Ann Oncol. 2013 Sep;24(9):2371-6. doi: 10.1093/annonc/mdt205. Epub 2013 May 30. Ann Oncol. 2013. PMID: 23723294 Free PMC article.

9

Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma.

Cumberbatch M, Tang X, Beran G, Eckersley S, Wang X, Ellston RP, Dearden S, Cosulich S, Smith PD, Behrens C, Kim ES, Su X, Fan S, Gray N, Blowers DP, Wistuba II, Womack C. Cumberbatch M, et al. Among authors: dearden s. Clin Cancer Res. 2014 Feb 1;20(3):595-603. doi: 10.1158/1078-0432.CCR-13-1638. Epub 2013 Nov 27. Clin Cancer Res. 2014. PMID: 24284056 Free PMC article.

10

Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review.

Sherwood J, Dearden S, Ratcliffe M, Walker J. Sherwood J, et al. Among authors: dearden s. J Exp Clin Cancer Res. 2015 Sep 4;34(1):92. doi: 10.1186/s13046-015-0207-9. J Exp Clin Cancer Res. 2015. PMID: 26338018 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters